Kornitzer Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Kornitzer Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-142,800	Closed	-$3.45M	–	541
2019 Q4	$3.45M	Sell	142,800 -140,735	-50%	-$2.91M	0.06%	283
2019 Q3	$5.45M	Buy	283,535 +131,680	+87%	+$3.02M	0.1%	254
2019 Q2	$4.49M	Sell	151,855 -855	-0.6%	-$32.9K	0.08%	258
2019 Q1	$7.25M	Sell	152,710 -21,050	-12%	-$927K	0.13%	209
2018 Q4	$6.27M	Buy	173,760 +9,285	+6%	+$436K	0.13%	202
2018 Q3	$10.1M	Buy	+164,475	New	+$10.6M	0.16%	185

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Kornitzer Capital Management's AERI Position: Q1 2020 in Review

Kornitzer Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q1 2020, closing a stake of 142,800 shares — an estimated $3.45M sold.

Kornitzer Capital Management first reported a position in AERI in Q3 2018 and held it in 6 quarters. The position peaked at $10.1M in Q3 2018. 155 funds tracked by Wall St. Rank hold AERI as of Q1 2020.

Kornitzer Capital Management reported no remaining Aerie Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Kornitzer Capital Management sold 142,800 Aerie Pharmaceuticals shares in Q1 2020, an estimated $3.45M.
Kornitzer Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2018 and held it in 6 quarters.
Kornitzer Capital Management's Aerie Pharmaceuticals position peaked at $10.1M in Q3 2018.
155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2020.

Based on Kornitzer Capital Management's 13F filing for Q1 2020, filed 30 Apr 2020.